
Newron Pharmaceuticals has announced the approval for its ENIGMA-TRS phase 3 development programme evaluating evenamide as an add-on therapy to …
Merck Serono has returned the rights to the Parkinson’s disease drug safinamide back to Newron. The decision comes after the …
NIHR chief scientific adviser visits Huddersfield health innovation campus
One in three UK women with migraine say symptoms taken less seriously
Report highlights scope to expand day surgery
Sygnature formalises drug discovery collaboration with X-Chem
Codis appoints Steven Facer as chief commercial officer

